Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis

Conditions: Dermatitis, Atopic Interventions: Drug: Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611) Sponsors: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials